News summary

AbbVivia's vitiligo treatment drug upadacitinib received breakthrough treatment certificationabugarciablackmax3reelThe market potential is huge.

Newsletter text

AbbVie's new drugs are recognized by important drug regulators

AbbVie announced on May 24abugarciablackmax3reel, its candidate drug upadacitinib has been recognized as a breakthrough treatment drug by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration. The indication for this selective JAK inhibitor is for adolescent and adult patients with non-segmental vitiligo over the age of 12.

Currently, upadacitinib is in the critical Phase 3 clinical study to evaluate its effectiveness and safety in the treatment of vitiligo.